Literature DB >> 19425594

Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase.

Achelle A Edwards1, Jennifer M Mason, Keith Clinch, Peter C Tyler, Gary B Evans, Vern L Schramm.   

Abstract

Human purine nucleoside phosphorylase (PNP) belongs to the trimeric class of PNPs and is essential for catabolism of deoxyguanosine. Genetic deficiency of PNP in humans causes a specific T-cell immune deficiency, and transition state analogue inhibitors of PNP are in development for treatment of T-cell cancers and autoimmune disorders. Four generations of Immucillins have been developed, each of which contains inhibitors binding with picomolar affinity to human PNP. Full inhibition of PNP occurs upon binding to the first of three subunits, and binding to subsequent sites occurs with negative cooperativity. In contrast, substrate analogue and product bind without cooperativity. Titrations of human PNP using isothermal calorimetry indicate that binding of a structurally rigid first-generation Immucillin (K(d) = 56 pM) is driven by large negative enthalpy values (DeltaH = -21.2 kcal/mol) with a substantial entropic (-TDeltaS) penalty. The tightest-binding inhibitors (K(d) = 5-9 pM) have increased conformational flexibility. Despite their conformational freedom in solution, flexible inhibitors bind with high affinity because of reduced entropic penalties. Entropic penalties are proposed to arise from conformational freezing of the PNP.inhibitor complex with the entropy term dominated by protein dynamics. The conformationally flexible Immucillins reduce the system entropic penalty. Disrupting the ribosyl 5'-hydroxyl interaction of transition state analogues with PNP causes favorable entropy of binding. Tight binding of the 17 Immucillins is characterized by large enthalpic contributions, emphasizing their similarity to the transition state. Via introduction of flexibility into the inhibitor structure, the enthalpy-entropy compensation pattern is altered to permit tighter binding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19425594      PMCID: PMC2711852          DOI: 10.1021/bi9005896

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  38 in total

1.  Interactions of trimeric purine nucleoside phosphorylases with ground state analogues--calorimetric and fluorimetric studies.

Authors:  Beata Wielgus-Kutrowska; Joachim Frank; Antonin Holý; Gertraud Koellner; Agnieszka Bzowska
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2003 May-Aug       Impact factor: 1.381

2.  The thermodynamics of protein-ligand interaction and solvation: insights for ligand design.

Authors:  Tjelvar S G Olsson; Mark A Williams; William R Pitt; John E Ladbury
Journal:  J Mol Biol       Date:  2008-10-09       Impact factor: 5.469

Review 3.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

4.  Thermodynamics of peptide inhibitor binding to HIV-1 gp41.

Authors:  J L Cole; V M Garsky
Journal:  Biochemistry       Date:  2001-05-15       Impact factor: 3.162

5.  Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase.

Authors:  Andrzej Lewandowicz; Peter C Tyler; Gary B Evans; Richard H Furneaux; Vern L Schramm
Journal:  J Biol Chem       Date:  2003-07-03       Impact factor: 5.157

6.  Crystal structure of human purine nucleoside phosphorylase at 2.3A resolution.

Authors:  Walter Filgueira de Azevedo; Fernanda Canduri; Denis Marangoni dos Santos; Rafael Guimarães Silva; Jaim Simões de Oliveira; Luiz Pedro Sório de Carvalho; Luiz Augusto Basso; Maria Anita Mendes; Mário Sérgio Palma; Diógenes Santiago Santos
Journal:  Biochem Biophys Res Commun       Date:  2003-08-29       Impact factor: 3.575

7.  Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.

Authors:  Gary B Evans; Richard H Furneaux; Andrzej Lewandowicz; Vern L Schramm; Peter C Tyler
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

8.  Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the Mannich reaction.

Authors:  Gary B Evans; Richard H Furneaux; Peter C Tyler; Vern L Schramm
Journal:  Org Lett       Date:  2003-10-02       Impact factor: 6.005

9.  Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases.

Authors:  Andrzej Lewandowicz; Vern L Schramm
Journal:  Biochemistry       Date:  2004-02-17       Impact factor: 3.162

10.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

View more
  23 in total

Review 1.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.

Authors:  Vern L Schramm
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

2.  Transition States and transition state analogue interactions with enzymes.

Authors:  Vern L Schramm
Journal:  Acc Chem Res       Date:  2015-04-07       Impact factor: 22.384

3.  Catalytic site conformations in human PNP by 19F-NMR and crystallography.

Authors:  Javier Suarez; Antti M Haapalainen; Sean M Cahill; Meng-Chiao Ho; Funing Yan; Steven C Almo; Vern L Schramm
Journal:  Chem Biol       Date:  2013-02-21

4.  Multiple cholesterol recognition/interaction amino acid consensus (CRAC) motifs in cytosolic C tail of Slo1 subunit determine cholesterol sensitivity of Ca2+- and voltage-gated K+ (BK) channels.

Authors:  Aditya K Singh; Jacob McMillan; Anna N Bukiya; Brittany Burton; Abby L Parrill; Alex M Dopico
Journal:  J Biol Chem       Date:  2012-04-03       Impact factor: 5.157

5.  Entropy-driven binding of picomolar transition state analogue inhibitors to human 5'-methylthioadenosine phosphorylase.

Authors:  Rong Guan; Meng-Chiao Ho; Michael Brenowitz; Peter C Tyler; Gary B Evans; Steven C Almo; Vern L Schramm
Journal:  Biochemistry       Date:  2011-11-07       Impact factor: 3.162

6.  Four generations of transition-state analogues for human purine nucleoside phosphorylase.

Authors:  Meng-Chiao Ho; Wuxian Shi; Agnes Rinaldo-Matthis; Peter C Tyler; Gary B Evans; Keith Clinch; Steven C Almo; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

Review 7.  Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.

Authors:  Rodrigo G Ducati; Hilda A Namanja-Magliano; Vern L Schramm
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

8.  Conformational dynamics in human purine nucleoside phosphorylase with reactants and transition-state analogues.

Authors:  Jennifer S Hirschi; Karunesh Arora; Charles L Brooks; Vern L Schramm
Journal:  J Phys Chem B       Date:  2010-10-11       Impact factor: 2.991

9.  Distortional binding of transition state analogs to human purine nucleoside phosphorylase probed by magic angle spinning solid-state NMR.

Authors:  Mathew J Vetticatt; Boris Itin; Gary B Evans; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

Review 10.  Glycosidase inhibition: assessing mimicry of the transition state.

Authors:  Tracey M Gloster; Gideon J Davies
Journal:  Org Biomol Chem       Date:  2009-11-05       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.